drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A HER2-targeted dual antibody–drug conjugate (ADC) administered intravenously every 3 weeks as neoadjuvant therapy. It binds HER2 (ErbB2) on tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill HER2-expressing cells; it may also dampen HER2 signaling and engage Fc-mediated immune effector functions, impacting downstream PI3K/AKT and MAPK pathways.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted antibody–drug conjugate that binds HER2 (ErbB2) on tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill HER2-expressing cells; it may also attenuate HER2 signaling and recruit Fc-mediated immune effector functions, impacting downstream PI3K/AKT and MAPK pathways.
drug_name
TQB2102 for injection
nct_id_drug_ref
NCT06198751